News

Treatment with Trikafta triggered diabetes remission in four people with cystic fibrosis (CF) at a center in Australia, with each of these patients experiencing complete resolution of CF-related diabetes, or CFRD, after starting on the approved triple therapy. In all four cases, the patients were able to stop…

A young man with cystic fibrosis (CF) no longer had gallbladder complications one year after starting treatment with the CF medication Trikafta, according to a case report from Italy. “To the best of our knowledge this is the first case reported in literature” of Trikafta successfully treating gallbladder…

Although parents of children with cystic fibrosis (CF) recognize the benefits of their children getting physical activity in schools, they see certain barriers in the school setting as preventing daily exercise for their children. Teachers’ misconceptions about CF, a failure to prioritize physical activity, and the physical limitations of…

Cilia, the structures on the surface of respiratory cells that help propel mucus out of the airways, have altered movement patterns in people with cystic fibrosis (CF), a study from Belgium found. The researchers believe these abnormalities likely stem from inflammation and contribute to impaired mucociliary clearance (MCC) in…

A cystic fibrosis (CF) therapy slightly but significantly increased diversity in the lung microbiome, the community of microorganisms found in the lungs, in adolescents with the disease, a study in Switzerland found. Treatment with Trikafta was specifically linked to an increase in commensal bacteria, those commonly present in healthy…

There could be many genes beyond CFTR that influence cystic fibrosis (CF) severity and treatment responses, according to a review study. Across 70 different studies, dozens of these so-called genetic modifiers were found to affect the severity of various CF symptoms. Mutations in a few of them were…

A study will explore why some people with cystic fibrosis (CF) respond better to Trikafta than others. The five-year study, led by Arkansas Children’s Research Institute, is being funded through a $2.9 million grant from the National Institutes of Health (NIH). The project is being led by Jennifer…

A clinical trial assessing the safety and tolerability of CMTX-101, an antibody-based therapy for cystic fibrosis (CF) lung infections, has started its second part. Phase 2a of the Phase 1b/2a trial (NCT06159725) aims to enroll up to 41 adults with CF at several sites in the U.S., treatment developer…

Chronic infection with the hepatitis E virus (HEV) may be linked to pig-derived pancreatic enzyme replacement therapy (PERT) in people with cystic fibrosis (CF) who underwent lung transplants, a study found. CF patients in general had disproportionately higher rates of antibodies against HEV, regardless of transplant status, and…

The abundance of Pseudomonas bacteria and related virulence factors in the lungs of people with cystic fibrosis (CF) after a transplant may raise their risk of a progressive decline in lung function and organ rejection, according to a recent study. Virulence is the ability of a microorganism to cause…